Neoadjuvant Immunotherapy for Hepatocellular Carcinoma.
Thomas U Marron1,2,3,4,5,6,7, Myron Schwartz1,2,3,4,6,7, Virginia Corbett1,3,5,6,7
1The neoAdjuvant Research Group to Evaluate Therapeutics (TARGET), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Journal of Hepatocellular Carcinoma
|July 7, 2022
Summary
Hepatocellular carcinoma (HCC) treatment is improving with new targeted and immunotherapies. Neoadjuvant immunotherapy shows promise for resectable HCC, with early studies indicating significant pathologic responses.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Cancer immunotherapy
- Surgical oncology
Background:
- Hepatocellular carcinoma (HCC) incidence is rising globally.
- Current treatment options for advanced HCC have recently expanded with targeted and immunotherapies.
- Surgical resection is a curative option for early HCC, but recurrence rates remain high with no effective perioperative therapies.
Purpose of the Study:
- To explore the potential of neoadjuvant immunotherapy for resectable hepatocellular carcinoma (HCC).
- To review recent advancements in HCC treatment, focusing on perioperative immunotherapy strategies.
Main Methods:
- Review of recent clinical studies and advancements in HCC treatment paradigms.
- Analysis of neoadjuvant immunotherapy approaches, including anti-PD-1 antibodies, in resectable HCC.
Main Results:
- New targeted and immunotherapies have improved outcomes for advanced HCC.
- Early studies of neoadjuvant anti-PD-1 antibodies in resectable HCC show significant pathologic responses.
- Neoadjuvant immunotherapy demonstrates potential to improve outcomes in resectable HCC.
Conclusions:
- The outlook for HCC patients is improving due to advancements in both early and advanced disease treatments.
- Neoadjuvant immunotherapy represents a promising strategy to improve survival for patients with resectable HCC.
- Further large-scale registrational studies are warranted to validate the efficacy of neoadjuvant immunotherapy for HCC.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
01:30Cancer Vaccines
503
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
503
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
260
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
260